The KLOW blend autoinjector pen is a preloaded 3ml research device containing a four-component peptide solution at 80mg/ml. The components are KPV, BPC-157, TB-500 and GHK-Cu. Each has an independently characterised molecular target, spanning NF-κB suppression, VEGFR2 signalling, actin sequestration and copper coordination.
Specification Table
KLOW blend autoinjector pen: device and component data
| Property |
Value |
| Device format |
Preloaded autoinjector pen, glass cartridge |
| Fill volume |
3 ml |
| Solution concentration |
80 mg/ml total peptide |
| Total peptide in device |
240 mg |
| Component 1 |
KPV (Lys-Pro-Val) |
| Component 2 |
BPC-157 |
| Component 3 |
TB-500 (thymosin β4) |
| Component 4 |
GHK-Cu (copper tripeptide) |
| Component ratio |
Not published on the product record. Confirm against the certificate of analysis |
| CAS, KPV |
67727-97-3 |
| CAS, BPC-157 |
137525-51-0 |
| CAS, TB-500 / thymosin β4 |
77591-33-4 |
| CAS, GHK-Cu |
89030-95-5 |
| Molecular weight, KPV |
342.43 g/mol |
| Molecular weight, BPC-157 |
1419.55 g/mol |
| Molecular weight, thymosin β4 |
4963.55 g/mol |
| Molecular weight, GHK-Cu |
401.91 g/mol |
| Target, KPV |
NF-κB signalling, via PepT1-mediated uptake |
| Target, BPC-157 |
VEGFR2, with downstream Akt and eNOS activation |
| Target, TB-500 |
Globular actin (G-actin) sequestration |
| Target, GHK-Cu |
Copper(II) coordination, fibroblast matrix protein synthesis |
| Reconstitution required |
None. Supplied as solution |
| Storage |
2-8°C, protected from light |
| Solution stability |
Not established for this four-component mixture |
| Regulatory status |
No approved human or veterinary formulation for any component |
What Does the Preloaded Format Change?
Search queries reaching this page are overwhelmingly about the device rather than the chemistry. Pen, premixed pen, peptide pen. That tells you what the audience is actually evaluating before they get anywhere near the molecules themselves.
A preloaded pen removes the reconstitution step, and with it a substantial source of variability. Manual reconstitution introduces error at several points: diluent volume measurement, incomplete dissolution, shear from over-agitation, and adsorptive loss during transfer. Every one of those affects delivered concentration, and none announces itself visually.
The tradeoff is that a preloaded device fixes the concentration at manufacture. There is no option to prepare a different working concentration without diluting from the device, which introduces its own handling step. For a study needing a concentration series, a lyophilized vial offers more flexibility.
The other tradeoff is time. A solution has been sitting in solution since it was filled, whereas a lyophilized cake has been dry. For multi-component peptide mixtures that difference matters, as the next section explains.
What Are the Four Components Doing?
Four peptides carrying four separately characterised targets, with no mechanistic overlap between any of them.
KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, residues 11 to 13. It enters cells through the PepT1 di- and tripeptide transporter, and published work reports reduced NF-κB activation downstream (Dalmasso et al., Gastroenterology, 2008).
BPC-157 is a fifteen-residue fragment of a protein found in human gastric juice. Published work associates it with increased VEGFR2 expression and time-dependent activation of the VEGFR2-Akt-eNOS pathway in vascular endothelial cells (Hsieh et al., Journal of Molecular Medicine, 2017).
TB-500 refers to thymosin β4, a 43-residue peptide whose defining property is high-affinity binding to globular actin. It sequesters G-actin monomers so they cannot polymerise into filaments, which places it directly inside the cytoskeletal dynamics governing cell migration.
GHK-Cu is a copper-coordinated tripeptide. Published work reports stimulation of collagen synthesis in cultured dermal fibroblasts across picomolar to nanomolar concentrations, with the effect specific to the sequence and its copper coordination rather than to copper delivery generally.
Why Does Solution-State Storage Complicate a Four-Peptide Mixture?
A lyophilized cake is chemically quiet, which is the entire reason peptides ship in that form. Water is largely absent, molecular mobility is low, and degradation proceeds slowly. That is the entire reason peptides are supplied lyophilized.
A solution in a glass cartridge is not quiet at all. Hydrolysis, oxidation, deamidation and aggregation all proceed at rates that depend on pH, temperature, ionic strength and what else is present. With four peptides in the same solution, each is exposed to the others and to whatever the excipient system contributes.
The copper component adds a specific consideration. Copper(II) participates in redox chemistry and can catalyse oxidation of susceptible residues. Thymosin β4 contains a methionine residue, and methionine is among the residues most vulnerable to metal-catalysed oxidation. Whether that occurs at a meaningful rate in this formulation is not something any published dataset addresses.
None of this means the product is unstable. It means the stability question is real, unresolved in the literature, and worth confirming against manufacturer data rather than assumed from the properties of the individual peptides.
What Is Not Established About the KLOW Blend Autoinjector Pen?
The component ratio does not appear on the product record available here. Total concentration is 80 mg/ml across 3 ml, giving 240 mg of peptide in the device, but how that divides between four components is not published on the listing. That single number determines every molar calculation a researcher would need to make, so it should be obtained from the certificate of analysis before any quantitative work.
The combination has no published controlled study. Each component has independent literature of varying depth, and BPC-157 and GHK-Cu are reasonably well covered. No study has examined all four together, and no ratio-optimisation data exists for this or any similar four-peptide arrangement.
Solution stability over the device shelf life is not published. Neither is the excipient system, which affects both stability and any downstream assay the solution enters.
This is a convenience format for a combination whose combined behaviour has not been characterised. That is a reasonable thing to sell and a reasonable thing to buy, provided nobody mistakes the convenience for evidence.
How Should Delivered Volume Be Verified?
A pen introduces a variable that a vial and syringe does not, which is the delivery mechanism itself. Spring-driven actuation is reproducible while everything sits within specification. It drifts when anything does not.
Gravimetric verification is the simplest check available and takes only a few minutes to run. Actuate the device onto a tared weighing vessel and record the mass delivered, then convert using solution density. Repeating across several actuations gives both accuracy against nominal volume and precision across draws, and it takes minutes.
Temperature is the main confounder in that measurement. Perform verification at the temperature the device will actually be used at, since a check run on a device straight from refrigeration will not describe its behaviour after equilibration.
First-actuation behaviour deserves separate attention. Many pen mechanisms under-deliver on the first actuation after a period of rest, because of air in the delivery path or seal relaxation. Where a priming step is specified it should be followed and recorded. Where none is specified, the first draw should be treated as suspect until gravimetric data shows otherwise.
For a four-component solution, an under-delivered volume shifts every component proportionally, so the ratio between them holds while the absolute amount does not. That is the better of the two possible failure modes, and it is still a failure mode worth catching.
Why Four Components Rather Than One
The formulation rationale is worth stating plainly, and so is the question of what it fails to establish.
Each of the four peptides engages a different part of tissue biology. GHK-Cu associates with matrix protein synthesis. BPC-157 associates with vascular signalling through VEGFR2. TB-500 acts on actin dynamics and therefore on cell migration. KPV suppresses NF-κB-driven inflammatory signalling.
Laid out that way the combination has an obvious logic: build matrix, support vasculature, enable migration, restrain inflammation. Four processes that really do operate together in tissue.
What that logic does not establish is that combining the four compounds produces coordinated action on those four processes. Each was characterised alone, in its own model system, usually at concentrations chosen for that system. Putting them in one solution does not make their individual findings additive, and no published work has tested whether it does. The rationale is a hypothesis, and a reasonable one, rather than a finding.
Handling the Device in Laboratory Practice
Store at 2-8°C and protect from light. The copper component makes light exclusion more than a formality, since copper(II) complexes are photosensitive and the solution is not shielded by a lyophilized matrix.
Allow the device to reach ambient temperature before use. Cold solutions are more viscous, and viscosity affects delivery accuracy in a spring-driven mechanism. This is a routine consideration with pen devices and a common source of volume error.
Inspect the solution before each use. It should be clear and free of particulate. A colour shift away from the expected blue-violet tint contributed by the copper component, or any cloudiness, indicates a change that has not been characterised and the device should be set aside.
Record device lot number, date of first use, storage temperature history where available, and the volume drawn for each experiment. For a device used across multiple sessions, the interval between first use and each subsequent draw is an experimental variable.
Published Literature
Traced to the publisher record or a primary index. Note what is absent from the list: every entry covers a single component, and not one of them covers the four peptides in combination.
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. Gastroenterology. 2008;134(1):166-178.
- Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, Wang JS, Chang VH, Pang JS. Journal of Molecular Medicine. 2017;95(3):323-333.
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Expert Opinion on Biological Therapy. 2012;12(1):37-51.
- Pickart L, Margolina A. International Journal of Molecular Sciences. 2018;19(7):1987. PMID: 29986520
- Sikiric P, Seiwerth S, Rucman R, et al. Current Pharmaceutical Design. 2011;17(16):1612-1632. PMID: 21548867
Frequently Asked Questions
What is the KLOW blend autoinjector pen?
A preloaded 3ml research device holding a four-peptide solution at 80mg/ml, which comes to 240 mg of total peptide across KPV, BPC-157, TB-500 and GHK-Cu. No reconstitution step is required. It is supplied for laboratory research use only and is not approved for human or veterinary use.
What are the four components and their targets?
KPV suppresses NF-kappa-B signalling after entering cells through PepT1, BPC-157 is associated with raised VEGFR2 expression and downstream Akt and eNOS activation, TB-500 binds globular actin and holds it out of the polymerising pool, and GHK-Cu coordinates copper while stimulating fibroblast collagen synthesis. Four peptides. Four separate mechanisms with no overlap.
What is the ratio between the four peptides?
It does not appear on the product record available here, which is a genuine gap rather than an omission from this page. Total concentration is 80mg/ml across 3ml. How that divides between four components determines every molar calculation, so obtain it from the lot-specific certificate of analysis before starting quantitative work.
How does a preloaded pen compare with a lyophilized vial?
The pen removes reconstitution along with the variability it introduces, meaning diluent measurement error, incomplete dissolution, shear from over-agitation and adsorptive loss during transfer all disappear as concerns. In exchange, concentration is fixed at manufacture. A study needing a concentration series has less flexibility than it would with a vial.
Why does solution storage matter for a peptide mixture?
A lyophilized cake is chemically quiet because water is largely absent and molecular mobility is low, which is the entire reason peptides ship in that form rather than as solutions. A filled cartridge is not quiet. Hydrolysis, oxidation, deamidation and aggregation all proceed at rates set by pH, temperature and whatever else shares the solution.
Does the copper component affect the other peptides?
Possibly, and nothing published settles it either way, which is worth knowing before assuming the four components sit inertly alongside one another for the shelf life of the device. Copper(II) participates in redox chemistry. Thymosin beta-4 contains a methionine, and methionine is among the residues most vulnerable to metal-catalysed oxidation.
Is TB-500 the same as thymosin beta-4?
In current usage the two are generally treated as interchangeable, both referring to the full 43-residue peptide with CAS 77591-33-4 and molecular weight 4963.55, though this was not always the case. The name TB-500 originally denoted a fragment. Some suppliers still use it that way, so confirming which molecule a preparation actually contains remains worthwhile.
Why should the device reach room temperature before use?
Cold solutions are more viscous, and viscosity affects delivery accuracy in a spring-driven mechanism, which makes a device used straight from refrigeration a predictable source of volume error that nobody notices at the time. Let it equilibrate first. The wait costs nothing and removes a variable.
What should be inspected before each use?
The solution should be clear and free of any particulate matter, and the blue-violet tint contributed by the copper component should look the same as it did on the previous draw. A colour shift indicates an uncharacterised change. Set the device aside, log the observation, and do not proceed with that draw.
How should delivered volume be verified?
Gravimetrically, by actuating the device onto a tared weighing vessel, recording the delivered mass and converting through solution density, repeated across several actuations to capture both accuracy against nominal volume and precision between draws. Run the check warm. A measurement taken cold will not describe how the device behaves in use.
Why treat the first actuation as suspect?
Many pen mechanisms under-deliver on the first actuation after a rest period, because air enters the delivery path or seals relax, and this is well known among people who use these devices routinely and entirely invisible to anyone who does not. Follow any specified priming step. Where none is specified, let gravimetric data establish the behaviour.
Compliance Statement
The KLOW blend autoinjector pen is sold exclusively for laboratory research use. It is not a drug, food, or cosmetic product, and it is not a dietary product of any kind. It is not approved by the FDA or any comparable authority for human or veterinary use, and no published controlled study has examined these four peptides in combination. This product is not intended to diagnose, treat, cure, or prevent any disease. It must not be given to humans or animals. Purchase is restricted to qualified researchers and institutions operating within applicable laws. All handling is the responsibility of the purchasing laboratory.
14 reviews for Preloaded Autoinjector | KLOW Blend | 3ml Pen | 80mg/ml